Y-mAbs Therapeutics
Joris Wilms serves as SVP, Chief Operating Officer. Mr. Wilms has extensive industry experience in clinical development, with a focus in oncology and hematology indications. He has been responsible for overseeing several first-in-human studies and pivotal clinical trials, leading to the approval of two monoclonal antibodies. Previous positions include VP, Clinical Trial Services and Pharmacovigilance, at KLIFO A/S, and Associate Director, Clinical Development, at Genmab A/S. Mr. Wilms received his MSc Pharm from the University of Groningen, Netherlands.
This person is not in any offices
Y-mAbs Therapeutics
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.